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Surgical procedure and clinical evaluation
After detailed explanations of the risks and potential bene its of the procedure, informed written consent was obtained from each DBS patient. Implantation of Medtronic quadripolar 3387 DBS electrodes (Medtronic Inc., Minneapolis, MN, USA) bilaterally into the STN was performed in one session under stereotaxic guidance. Intraoperative stimulation trials were carried out to determine if the stimulation improved clinical effects. The pulse generators (Kinetra, Medtronic, Minneapolis, USA) were placed under the skin in the subclavicular area in a staged procedure (one week later). Stimulation was initiated 1 d after pulse generator placement and electrical parameters were adjusted according to clinical improvements and side effects.
The motor scores of the Uni ied Parkinson's Disease Rating Scale (UPDRS) for each DBS patient were determined on the day before the operation and at 1 week, 3 months, 1 year, and 2 years after starting chronic stimulation (stimulator on) in both on-medication and off-medication states. The off-med samples were obtained after 1 hour off-medication states. Statistical analysis was performed on the UPDRS scores to measure improvements. The evaluator was blinded to the CSF results.
CSF samples
CSF specimens were obtained by lumbar puncture (LP). For each DBS patient, six consecutive CSF samples were obtained during the perioperative period on the day before DBS electrodes implantation, the day before pulse generator placement(one week after the irst time CSF collection), the 7 th day after stimulation starting(one week after the second time CSF collection), and during the follow-up period at 3, 12 and 24 months after the stimulator was turned on. All LPs were performed at 7 am following fasting and 10 ml of CSF was obtained from each LP from each participant. The cell count, glucose, total protein, and pH of each CSF specimen were assessed to rule out routine abnormalities. After collection, CSF samples were brie ly centrifuged at 2,000 g for 10 min to pellet any cell debris, before being frozen and stored in polypropylene tubes at -80°C in 1 ml aliquots until analysis.
Sample preparation for electrophoresis
Nine CSF samples obtained during the perioperative period from three consecutive DBS patients and three CSF samples from age and sex-matched controls were selected for 2-D DIGE analysis. The depletion step was not performed, so as to avoid the loss of potential protein candidates in CSF. All selected CSF samples were precipitated with 100% ice-cold acetone in a 4:1 ratio of acetone to CSF at -20°C for at least 4 h to remove salt from the sample before centrifugation at 12,000 g at 4°C for 10 min. The resulting pellet was washed three times with 100% ice-cold acetone and air-dried. The precipitated proteins were solubilized in a lysis buffer containing 7 M urea, 2 M thiourea, 4% CHAPS, 65 mM Tris, 2% (v/v) protease inhibitors (protease inhibitor cocktail tablets, Roche Diagnostics, Mannheim, Germany). Protein concentrations were determined by the Bradford method with bovine serum albumin as protein standard: mean±SD, group A:5.32±0.12 mg/ml;group B:5.87±0.14 mg/ml; group C: 6.15±0.11 mg/ml; group D: 5.68±0.09 mg/ml. The potential protein losses during the acetone precipitation was about 15%
2-D DIGE
CSF samples for 2-D DIGE analysis were divided into four groups with three samples per group: control group (group A), PD group (group B, for which samples were obtained 1 day before DBS electrode implantation), pre-DBS group (group C, for which samples were obtained 1 day before pulse generator placement), and the one-week group (group D, for which samples were obtained on the 7 th day after starting stimulation). There was no signi icant difference in total CSF protein concentration between any two groups. Samples were labeled with N-hydroxysuccinimidyl ester-derivatives of the cyanine dyes Cy2, Cy3, and Cy5 following the protocol of Amersham Biosciences so that 50 g of protein taken from patient and control samples was minimally labeled with 400 pmol of Cy3 or Cy5, respectively. Cy2 was used to label the same amount of internal standard, resulting from the pooling of aliquots of all patients and controls. After incubating on ice and in the dark for 30 min, the reaction was terminated by adding 1 l of 10 mM lysine. The three labeled samples were then combined (150 g) and diluted with rehydration buffer (8 M urea, 2% CHAPS, 18 mM DTT, 0.5% carrier ampholyte pH 3-10NL) to 250 l. The combined samples were loaded on a pH gradient strip (13 cm, pH 3-10, nonlinear) for isoelectric focusing (IEF) on an Ettan IPGphor system (Amersham Biosciences, Uppsala, Sweden). After active rehydration for 12 h at 30 V at 20°C, IEF was Intragel spot detection and quanti ication and intergel matching and quanti ication were performed automatically using the Differential In-gel Analysis (DIA) and Biological Variation Analysis (BVA) modules of DeCyder software version 6.5 (Amersham Biosciences). The gel with the highest spot count was considered the master gel. Using DIA, the Cy2, Cy3, and Cy5 images for each gel were merged, spot boundaries were automatically detected, and normalized spot volumes (protein abundance) were calculated. During spot detection, the estimated number of spots was set at 2000, and the exclude ilter was set as follows: slope 1.1; area<100; peak height<100; and volume<1000. The resulting spot maps were exported to the BVA module. Gel-to-gel matching of the standard spot maps from each gel, followed by statistical analysis of protein abundance change between samples, was performed in the BVA module. Selection criteria for the detection of signi icantly changed protein spots were that protein spots presented at least in four of the six analyzed gels (in 12 of 18 analyzed images) and that the standardized average spot volume ratios exceed 1.5 with statistical signi icance (Student's t-test, P<0.05). In the case of 3 or more sample groups, one-way ANOVA at 95% statistical con idence (signi icance level, P<0.05) was set. False discovery rate(FDR) correlations [19] were applied according to the DeCyder manual.
Protein digestion and mass spectrometry
For mass spectrometric analysis, differentially expressed protein spots of interest were excised from the gel with the Ettan spot picker (Amersham Biosciences-GE Healthcare) and subjected to in-gel digestion with trypsin. Brie ly, gel plugs were destained with 30% acetonitrile (ACN) in 100 mM ammonium bicarbonate (NH 4 HCO 3 ) for 20 min and vacuum dried. Digestion buffer (20 ng/ l trypsin in 20 mM NH 4 HCO 3 ) was then added and the samples were digested at room temperature overnight. Peptides were extracted twice with a solution containing 60% ACN and 0.1% tri luoroacetic acid (TFA). The extracted peptides were removed, dried and re-suspended in 50% ACN and 0.1% TFA. An equal volume of sample and -HCCA matrix (5 mg/ ml) were spotted and mixed on the MALDI-TOF target plate. Peptide mixtures were analyzed with a Bruker Daltonics AutoFlex TOF-TOF LIFT Mass Spectrometer (Bruker Daltonics, Bremen, Germany) in positive ion re lector mode. The accelerating potential was 20 kV with eight-shots per second. Each spectrum was internally calibrated using trypsin autolysis peaks (m/z 842.51 or 2211.10). The obtained peptide mass ingerprints spectra were analyzed by searching the non-redundant protein database National Centre for Biotechnology Information (NCBInr 20070810; 5366160 sequences, 1855569248 residues, and 193932 sequences after taxonomy ilter). Search parameters were set as follows: taxonomy: Homo sapiens; enzyme: trypsin; peptide mass tolerance: ±100 ppm; fragment mass tolerance: ±0.8 Da; peptide charge state: 1+; ixed modi ication: carbamidomethyl cysteine; maximum missed cleavages: 1. In all protein identi ications, the probability scores were greater than the score ixed as signi icant with a P value less than 0.05.
Samples for which unambiguous protein identity was not provided by MALDI-MS were further investigated through ESI-MS. RP-HPLC was performed using an Ettan TM MDLC (GE Healthcare) using a C18 column (0.15 mm 150 mm; Agilent Technologies, Palo Alto, CA, USA ) at a low rate of 10 l/min. The mobile phase conditions consisted of: Buffer A, 0.1% formic acid in water; and Buffer B, 0.1% formic acid in ACN. The peptides were sequentially eluted with a gradient of 4 to 100% Buffer B over 60 min. The mass spectral data were acquired on an ESI-linear ion trap mass spectrometer (LTQ, Thermo Finnigan, San Jose, CA) equipped with an electrospray interface and operated in positive ion mode. The temperature of the heated capillary was set at 170°C. A voltage of 3.3 kV applied to the ESI needle resulted in a distinct signal. Collision energy was automatically set by the system. After acquisition of a full scan mass spectrum, ten MS/MS scans were acquired for the next ten most intense ions using dynamic exclusion. The acquired MS/ MS spectra were automatically searched against a human protein database (ipi HUMAN v3.26) using the TurboSEQUEST program in the BioWorks™ 3.1 software suite. An accepted SEQUEST result had to have 
Western blotting analysis
All CSF samples were divided into seven groups with six samples per group, according to the time point at which the PD CSF samples were obtained: control group (group A), PD group (group B), pre-DBS group (group C), one-week group (group D), 3-months group (group E), 12-months group (group F) and 24-months group (group G). All CSF samples were used to con irm the selected data of proteomic analysis and were concentrated using ultra iltration. Protein concentrations were determined by the Bradford method before samples were boiled in the loading buffer (60 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol) for 5 min. There was no signi icant difference in total CSF protein content among groups. Fifty microgram protein of each sample was separated in 12.5% SDS-polyacrylamide gels and electrotransferred to a nitrocellulose membrane (Amersham). After blocking and rinsing, blots were incubated overnight at 4°C in one of the following primary antibodies: rabbit anti-apolipoprotein A-I polyclonal antibody ( 1:1000), chicken anti-human IgA polyclonal antibody (1:3000), mouse anti-human superoxide dismutase 3 monoclonal antibody (1:500), goat anti-human C4 antibody (1:500), and mouse anti-human tetranectin monoclonal antibody (1:500). All primary antibodies were purchased from Abcam (Cambridge, MA, USA) with the exception of anti-human C4 antibody (Calbiochem, San Diego, CA, USA). Immunoblots were probed with the respective horseradish peroxidase-conjugated secondary antibodies (1:5000; Invitrogen, Carlsbad, CA, USA) and detected using SuperSignal West Pico Chemiluminescent substrate (Pierce, Rockford, IL, USA). Each immunoblot was run in triplicate or more. Detection of -tubulin was conducted to con irm equal loading of samples and for normalization purposes. Bands were digitized and optical densities were analyzed using ImageMaster 2D Platinum (v.5.0, Amersham Biosciences). The densities of the protein bands were normalized to that of the -tubulin bands.
Statistical analysis
Statistical analysis was carried out using GraphPad Prism v4.0 statistical software (GraphPad Software Inc., San Diego, CA, USA). The data were subjected to either t-test or one-way ANOVA and differences were considered signi icant when P values were <0.05. To determine the biological coef icients of variation (CVi), spot volumes of all analyzed protein spots were exported from DeCyder. The CVi were calculated from the SA(standardized abundance)-values of protein spots across different sets of gels. The median of CVi values per used gel set yields the biological variation [20] .
Results
No signi icant perioperative complications occurred in any of the six DBS patients. The UPDRS motor scores signi icantly improved (P<0.05) after DBS in both on-medication and off-medication states, and DBS resulted in more signi icant therapeutic effects in the off- (Table 1 ). All the patients selected for our study were treated with L-DOPA in the dosage of 1500mg~2000mg per day before their admission for DBS therapy, and keep this dosage till one week after DBS therapy (mean±SD 1792±246mg/day). The dose of L-DOPA was gradually reduced after one week. Three months after the DBS therapy, it was decreased to 750mg~1250mg in all the patients (mean±SD: 1023 ±152mg/day).The mean daily antiparkinsonian treatment dose was decreased by 42% on average. Since then, the dosage was not changed in all patients during the follow-up period.
One patient discontinued the DBS therapy 8 months after surgery because of a suicide attempt. The electrodes were not removed during the follow-up period and both the suicidal thoughts and the therapeutic effect of DBS dissipated after discontinuation of the DBS therapy (Table 1) . For this patient, the L-DOPA was returned to the original dosage. Fig. 1 . Differentiated protein spots between the PD and control groups in the master gel image (Cy5-labeled) of CSF. Spots in the image were analyzed by DeCyder software and only spots with differences in standardized average spot volume ratios 1.5 and a t-test P value <0.05 are shown (marked in green circles). Spots that were not altered signi icantly between the PD and control groups but analyzed by mass spectrometry are marked in red circles. Only spots which were successfully identi ied after mass spectrometry and protein database interrogation are manually numbered. Graphs of standardized abundance for a differentiated protein spot can be generated automatically by the DeCyder software by displaying the abundance values relative to the pooled standard (Fig. 2) .Within these signi icantly altered protein spots from the A-B, B-C, and C-D groups, no identical protein spot was found in two paired groups except for one spot (spot No. 8), which emerged simultaneously in the paired PD/control (A-B) groups and PD/ pre-DBS (B-C) groups (Fig. 2) .
Of these differentially expressed spots, 25 spots from A-B-C-D groups comparison were present in all analyzed images. These spots were selected and subjected to mass spectrometry , and 11 were signi icantly changed between the PD and control groups, and spot 8 was also signi icantly changed between the PD and pre-DBS groups. Spot 9 was markedly up-regulated in the one-week group as compared to the pre-DBS group. By MS, spots 1 and 8 were identi ied as apoA-I, spot 9 was identi ied as EC-SOD, spot 4 was identi ied as tetranectin, spot 7 was identi ied as C4, and spot 11 was identi ied as an IgA fragment. Standard: internal standard; A: control group; B: PD group; C: pre-DBS group; D: one-week group; +: mean volume of each group.
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(MALDI-TOF or ESI) with a total of 21 proteins successfully identi ied. The MASCOT search engine of the MALDI-TOF instrument, which is based on the NCBI protein database, was used to identify peptide mass ingerprints and individual ion scores 65 were considered to be signi icant (Fig. 3) . These identi ied proteins were further con irmed in the SwissProt/ TrEMBL protein database. Of these 21 proteins, 13 were signi icantly altered in the PD group (group B) as compared with the control group (group A), which can be regarded as PDrelated proteins; 2 were signi icantly altered in the pre-DBS group as compared with the PD group (spots No. 8 and 14); 3 were signi icantly altered in the post-DBS one-week group as compared with pre-DBS group (spots No. 9, 16 and 17); all proteins were signi icantly altered in general group comparisons (A-B-C-D groups). The detailed information of identi ied proteins is presented in Table 2 .
To con irm the proteomic analysis indings, and also to determine the exact changes of these proteins in the follow-up period, ive proteins were selected for western blotting analysis. The relative intensity data had been normalized for tubulin. Normalization against tubulin performed on each individual gel.The results showed that protein bands for apoA-I, tetranectin, C4, IgA, and EC-SOD were clearly observed in all CSF samples. Semi-quantitative densitometric evaluation revealed that the expression levels of C4, IgA, tetranectin, and EC-SOD correlated well with the 2-D DIGE results while the expression levels of apoA-I partially differed from the 2-D DIGE results. Moreover, the expression levels of C4, apoA-I and IgA Fig. 3 . MASCOT search results and probability plots corresponding to apoA-I (spots 1 and 8), EC-SOD (spot 9), tetranectin (spot 4), C4 (spot 7), and IgA (spot 11). The m/z-values obtained for each protein spot were used to identify the protein by searching in protein databases. Probability-based MOWSE scores were estimated as ion scores -10*log 10 (P), where P is the probability. Individual ion scores 65 were considered to be signi icant (P<0.05). High probability scores were used to identify proteins. After mass spectrometry and protein database interrogation, our data demonstrated that a total of 21 proteins were identi ied in the CSF. In previous CSF proteomics in PD studies, several differentially expressed proteins such as apoA-I , complement C4, and Cystatin C were identi ied [22, 23] . Some of these 21 proteins were identi ied for the irst time in this work.
In order to con irm the results of the 2-D DIGE analysis, and also to know the exact changes of these proteins in the follow-up period, we further performed western blotting analysis on all collected CSF samples by using speci ic antibodies against apoA-I, tetranectin, C4, IgA and EC-SOD. The 2-D DIGE protein results were largely con irmed by western blotting analysis, except that of apoA-I. This discrepancy is possibly due to the fact that the antibody used for apoA-I is not isoform speci ic and that western blotting gives only information on total apoA-I immunoreactivity. Data from western blotting analysis revealed a signi icant increase in EC-SOD and tetranectin levels in the CSF of PD patients during the follow-up period, whereas the expression levels of C4, apoA-I and IgA were very stable. The changes in EC-SOD and tetranectin paralleled the observed improvement in parkinsonian signs and symptoms and it is of interest to note that the levels of EC-SOD and tetranectin signi icantly decreased upon withdrawal of DBS stimulation. These results suggest that the differences in the expression levels of EC-SOD and tetranectin are related to the STN DBS. Therefore, EC-SOD and tetranectin may serve as potential biomarkers in PD patients. Certainly, these preliminary indings need to be con irmed with a larger study. EC-SOD is found in the extracellular matrix of tissues and functions to prevent cell and tissue damage caused by extracellularly produced reactive oxygen species (ROS) [24] . Although the physiological roles of this enzyme in the brain are not completely understood, it is primarily localized in the mouse brain to the hippocampus, striatum, suprachiasmatic nuclei and the habenula [25] . In the present study, bilateral STN DBS induced an increased expression of EC-SOD in PD patients.
To date, the biological function of tetranectin has not been fully elucidated [26] . One previous study indicated that tetranectin was involved in the degradation of extracellular matrix proteins in the brain [27] . Immunohistochemistry showed tetranectin immunoreactivity in neurons and dendrites, and a lack of staining in glial cells in the cerebrum and cerebellum, and the source of tetranectin in the CSF is believed to be the central nervous system [28] . Our previous study demonstrated that tetranectin was present at reduced levels in PD patients in comparison to normal controls [29] . In the present study, we further con irmed these results and found that tetranectin levels were signi icantly elevated after STN DBS. Since tetranectin is involved in the degradation of proteins in the brain [27] , and accumulating evidence suggests that degeneration and loss of dopaminergic neurons in brain have links with abnormal protein aggregation [30] [31] [32] , it would seem reasonable to assume that elevated tetranectin levels following STN DBS would reduce abnormal protein aggregation.
Conclusion
Using proteomic techniques and western blotting, we have studied for the irst time proteome variations in the CSF of PD patients under pre-and post-DBS conditions in an attempt to elucidate the possible mechanisms of DBS. Our results revealed the presence of alterations in the levels of certain proteins in the CSF of PD patients during the perioperative and follow-up periods. Of these proteins, C4, apoA-I and IgA were stably expressed during the follow-up period while the levels of EC-SOD and tetranectin signi icantly increased. Our indings suggest that EC-SOD and tetranectin may serve as potential biomarkers of PD. But the exact roles of these two proteins in the brain still remain to be determined. Further validations of the results are required and should be performed in a larger cohort of DBS patients with a suf icient follow-up period. 
